Last reviewed · How we verify

Arm 2 boosted protease inhibitors and maraviroc

Kirby Institute · FDA-approved active Small molecule Quality 2/100

Arm 2 boosted protease inhibitors and maraviroc is a Small molecule drug developed by Kirby Institute. It is currently FDA-approved. Also known as: maraviroc, atazanavir, lopinavir, darunavir.

At a glance

Generic nameArm 2 boosted protease inhibitors and maraviroc
Also known asmaraviroc, atazanavir, lopinavir, darunavir, fosamprenavir
SponsorKirby Institute
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Arm 2 boosted protease inhibitors and maraviroc

What is Arm 2 boosted protease inhibitors and maraviroc?

Arm 2 boosted protease inhibitors and maraviroc is a Small molecule drug developed by Kirby Institute.

Who makes Arm 2 boosted protease inhibitors and maraviroc?

Arm 2 boosted protease inhibitors and maraviroc is developed and marketed by Kirby Institute (see full Kirby Institute pipeline at /company/kirby-institute).

Is Arm 2 boosted protease inhibitors and maraviroc also known as anything else?

Arm 2 boosted protease inhibitors and maraviroc is also known as maraviroc, atazanavir, lopinavir, darunavir, fosamprenavir.

What development phase is Arm 2 boosted protease inhibitors and maraviroc in?

Arm 2 boosted protease inhibitors and maraviroc is FDA-approved (marketed).

Related